PL3173400T3 - Leki zawierające modyfikacje krystaliczne (1R, 2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenolu - Google Patents
Leki zawierające modyfikacje krystaliczne (1R, 2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenoluInfo
- Publication number
- PL3173400T3 PL3173400T3 PL16203848T PL16203848T PL3173400T3 PL 3173400 T3 PL3173400 T3 PL 3173400T3 PL 16203848 T PL16203848 T PL 16203848T PL 16203848 T PL16203848 T PL 16203848T PL 3173400 T3 PL3173400 T3 PL 3173400T3
- Authority
- PL
- Poland
- Prior art keywords
- dimethylamino
- phenol
- propyl
- ethyl
- methyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07023728 | 2007-12-07 | ||
| EP16203848.3A EP3173400B1 (de) | 2007-12-07 | 2008-12-05 | Arzneimittel enthaltend kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| PCT/EP2008/010330 WO2009071310A1 (de) | 2007-12-07 | 2008-12-05 | Kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| EP08857298.7A EP2240431B1 (de) | 2007-12-07 | 2008-12-05 | Kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3173400T3 true PL3173400T3 (pl) | 2020-05-18 |
Family
ID=39272207
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08857298T PL2240431T3 (pl) | 2007-12-07 | 2008-12-05 | Krystaliczne modyfikacje (1R,2R)-3-(3-dimetyloamino-1-etylo-2-metyIopropylo)fenoIu |
| PL16203848T PL3173400T3 (pl) | 2007-12-07 | 2008-12-05 | Leki zawierające modyfikacje krystaliczne (1R, 2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenolu |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08857298T PL2240431T3 (pl) | 2007-12-07 | 2008-12-05 | Krystaliczne modyfikacje (1R,2R)-3-(3-dimetyloamino-1-etylo-2-metyIopropylo)fenoIu |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8134032B2 (pl) |
| EP (2) | EP2240431B1 (pl) |
| CN (3) | CN101939287B (pl) |
| CY (2) | CY1118976T1 (pl) |
| DK (2) | DK2240431T3 (pl) |
| ES (2) | ES2764451T3 (pl) |
| HR (2) | HRP20170481T1 (pl) |
| HU (2) | HUE031126T2 (pl) |
| IL (2) | IL206197A (pl) |
| LT (1) | LT2240431T (pl) |
| PL (2) | PL2240431T3 (pl) |
| PT (2) | PT2240431T (pl) |
| SI (2) | SI3173400T1 (pl) |
| WO (1) | WO2009071310A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004007905T2 (de) * | 2004-06-28 | 2008-05-08 | Grünenthal GmbH | Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid |
| US20100272815A1 (en) * | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
| US8288592B2 (en) | 2009-09-22 | 2012-10-16 | Actavis Group Ptc Ehf | Solid state forms of tapentadol salts |
| US20130116333A1 (en) | 2010-05-05 | 2013-05-09 | Ratiopharm Gmbh | Solid tapentadol in non-crystalline form |
| WO2012051246A1 (en) | 2010-10-12 | 2012-04-19 | Ratiopharm Gmbh | Tapentadol hydrobromide and crystalline forms thereof |
| WO2013111161A2 (en) * | 2012-01-10 | 2013-08-01 | Msn Laboratories Limited | Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof |
| WO2014023652A1 (en) * | 2012-08-06 | 2014-02-13 | Ratiopharm Gmbh | Pharmaceutical formulation comprising tapentadol and cyclodextrin |
| EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
| CZ307492B6 (cs) | 2014-02-04 | 2018-10-17 | Zentiva, K.S. | Pevná forma maleátu tapentadolu a způsob její přípravy |
| GB2523089A (en) * | 2014-02-12 | 2015-08-19 | Azad Pharmaceutical Ingredients Ag | Stable polymorph form B of tapentadol hydrochloride |
| PL3445742T3 (pl) | 2016-04-19 | 2020-05-18 | Ratiopharm Gmbh | Krystaliczny fosforan tapentadolu |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1027666C (zh) * | 1993-02-20 | 1995-02-15 | 袁晓辉 | 高分子聚合物正温度系数热敏电阻材料 |
| DE4426245A1 (de) * | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| DE10326097A1 (de) * | 2003-06-06 | 2005-01-05 | Grünenthal GmbH | Verfahren zur Herstellung von Dimethyl-(3-aryl-butyl)-aminverbindungen |
| DE602004007905T2 (de) * | 2004-06-28 | 2008-05-08 | Grünenthal GmbH | Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid |
| DE102005034974A1 (de) * | 2005-07-22 | 2007-04-19 | Grünenthal GmbH | Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen |
| US20070254960A1 (en) * | 2006-04-28 | 2007-11-01 | Gruenenthal Gmbh | Pharmaceutical combination |
-
2008
- 2008-12-05 PT PT88572987T patent/PT2240431T/pt unknown
- 2008-12-05 US US12/329,111 patent/US8134032B2/en active Active
- 2008-12-05 CN CN200880126383.XA patent/CN101939287B/zh not_active Expired - Fee Related
- 2008-12-05 DK DK08857298.7T patent/DK2240431T3/en active
- 2008-12-05 EP EP08857298.7A patent/EP2240431B1/de active Active
- 2008-12-05 PL PL08857298T patent/PL2240431T3/pl unknown
- 2008-12-05 ES ES16203848T patent/ES2764451T3/es active Active
- 2008-12-05 PT PT162038483T patent/PT3173400T/pt unknown
- 2008-12-05 PL PL16203848T patent/PL3173400T3/pl unknown
- 2008-12-05 ES ES08857298.7T patent/ES2623413T3/es active Active
- 2008-12-05 HR HRP20170481TT patent/HRP20170481T1/hr unknown
- 2008-12-05 HU HUE08857298A patent/HUE031126T2/en unknown
- 2008-12-05 EP EP16203848.3A patent/EP3173400B1/de active Active
- 2008-12-05 CN CN201410468436.3A patent/CN104447360B/zh not_active Expired - Fee Related
- 2008-12-05 HU HUE16203848A patent/HUE047275T2/hu unknown
- 2008-12-05 WO PCT/EP2008/010330 patent/WO2009071310A1/de not_active Ceased
- 2008-12-05 SI SI200832101T patent/SI3173400T1/sl unknown
- 2008-12-05 LT LTEP08857298.7T patent/LT2240431T/lt unknown
- 2008-12-05 CN CN201410468681.4A patent/CN104447361B/zh not_active Expired - Fee Related
- 2008-12-05 SI SI200831791A patent/SI2240431T1/sl unknown
- 2008-12-05 DK DK16203848T patent/DK3173400T3/da active
-
2010
- 2010-06-06 IL IL206197A patent/IL206197A/en active IP Right Grant
-
2015
- 2015-03-01 IL IL237478A patent/IL237478A0/en unknown
-
2017
- 2017-04-07 CY CY20171100414T patent/CY1118976T1/el unknown
-
2019
- 2019-12-04 CY CY20191101278T patent/CY1122416T1/el unknown
-
2020
- 2020-01-16 HR HRP20200067TT patent/HRP20200067T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3173400T1 (sl) | 2020-01-31 |
| WO2009071310A1 (de) | 2009-06-11 |
| CN104447361A (zh) | 2015-03-25 |
| PL2240431T3 (pl) | 2017-07-31 |
| PT3173400T (pt) | 2019-12-13 |
| SI2240431T1 (sl) | 2017-05-31 |
| CN101939287B (zh) | 2014-10-22 |
| DK2240431T3 (en) | 2017-04-10 |
| IL237478A0 (en) | 2015-04-30 |
| CN104447360A (zh) | 2015-03-25 |
| CY1118976T1 (el) | 2018-01-10 |
| ES2764451T3 (es) | 2020-06-03 |
| US8134032B2 (en) | 2012-03-13 |
| ES2623413T3 (es) | 2017-07-11 |
| IL206197A0 (en) | 2010-12-30 |
| EP2240431B1 (de) | 2017-01-25 |
| HRP20170481T1 (hr) | 2017-05-19 |
| LT2240431T (lt) | 2017-04-10 |
| IL206197A (en) | 2015-03-31 |
| HUE031126T2 (en) | 2017-07-28 |
| CY1122416T1 (el) | 2021-01-27 |
| CN104447360B (zh) | 2017-04-12 |
| HUE047275T2 (hu) | 2020-04-28 |
| PT2240431T (pt) | 2017-05-03 |
| DK3173400T3 (da) | 2019-11-25 |
| HRP20200067T1 (hr) | 2020-04-03 |
| US20090149534A1 (en) | 2009-06-11 |
| EP3173400A1 (de) | 2017-05-31 |
| EP2240431A1 (de) | 2010-10-20 |
| EP3173400B1 (de) | 2019-11-06 |
| CN101939287A (zh) | 2011-01-05 |
| CN104447361B (zh) | 2017-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3173400T3 (pl) | Leki zawierające modyfikacje krystaliczne (1R, 2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenolu | |
| IL255201A0 (en) | Process for the preparation of (r2, 1r)-3-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
| ZA200700774B (en) | Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride | |
| DK1786403T3 (da) | Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
| PL1786403T3 (pl) | Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol | |
| SI2086940T1 (sl) | Sol fumarata (alfa s, beta r)-6-bromo-alfa-(2-(dimetilamino)etil)-2-metoksi-alfa-1-naftalenil-beta- fenil-3-kinolinetanola | |
| ZA201001159B (en) | Stabilized tolterodine tartrate formulations |